Efficacy and Safety of Bictegravir-Based Regimen in Pregnant Women Living with HIV: A Case Report
| Autor: | Shaimaa Alsulami PharmD, BCPPS, Sultan N. Alotaibi PharmD, BCPS, BCIDP, Nader Damfu PharmD, BCPS, BCIDP, Doaa M. Aljefri PharmD, MSc, BCIDP, Hadeel Ahmed Altayib MD, Maher Alharbi MD |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Journal of the International Association of Providers of AIDS Care, Vol 21 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2325-9582 23259582 |
| DOI: | 10.1177/23259582221146110 |
| Popis: | Bictegravir (BIC) is included in international guidelines as the first line of therapy for patients living with Human Immunodeficiency Virus (HIV), either as initial therapy or as a replacement for patients with prior antiretroviral therapy (ART). Due to limited efficacy and safety data, BIC is currently not recommended during pregnancy. Data on the safety and efficacy of BIC during pregnancy were unavailable at the time of drug approval. In our case, BIC/TAF/FTC was effective in suppressing viral load (VL) in pregnancy, and there were no reported safety issues for the mother or the baby. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|